Teva UK Ltd, Ponlimsi (Denosumab) 60mg solution for injection in pre-filled syringe defect
The MHRA has published a Class 4 medicines defect notification for Ponlimsi (denosumab) 60mg solution for injection in pre-filled syringe.
Published: 4 June 2026
Teva UK Limited is reporting a labelling error on the carton for Ponlimsi (denosumab) 60mg solution for injection in pre-filled syringe. The carton states “For application to the skin” when the product is licensed for subcutaneous use.
Further information, advice and details of the affected batches can be found on the MHRA website.